secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0000950170-23-031128
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology expands board to 7, appoints Dr. Jakob Dupont as director contingent on Apexigen merger
--------------------------------------------------------------------------------

- Board size increased to seven members, effective upon closing of merger with Apexigen.
- Dr. Jakob Dupont appointed as Class III director, term expiring at 2024 annual meeting.
- Dr. Dupont executed voting agreement to support merger proposals; no other arrangements or family ties.
- Appointment contingent on merger completion; Dr. Dupont eligible for non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023031128/0000950170-23-031128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023031128/pyxs-20230628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-031128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer